- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01614509
Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
December 3, 2012 updated by: Min Sagong, Yeungnam University College of Medicine
This study compares the efficacy of intravitreal bevacizumab monotherapy only or combined therapy of posterior subtenon's triamcinolone acetonide and intravitreal bevacizumab for the treatment of macular edema associated with branch retinal vein occlusion.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Daegu, Korea, Republic of, 705-717
- Yeungnam University College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant must have macular edema associated branch retinal vein occlusion.
- The participant has retinal photographs, optical coherence tomography (OCT) and angiography of sufficient quality, allowing assessment of the macular area according to standard clinical practice.
- The participant must be willing and able to comply with the protocol.
Exclusion Criteria:
- The participant has BRVO with other ocular vascular diseases such as central retinal vein occlusion, hypertensive retinopathy, etc.
- The participant has any additional ocular diseases that have irreversibly compromised or could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy.
- The participant has a history of treatment for BRVO in the study eye with focal laser photocoagulation, intravitreal triamcinolone acetonide injection or intravitreal Bevacizumab injection
- The participant has a history of intraocular surgery (including lens replacement surgery).
- The participant has a history of ocular trauma, or current ocular or periocular infection (including any history of ocular herpes zoster or simplex).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monotherapy group
The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab.
The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions.
The bevacizumab is injected through the pars plana using a 30-gauge needle.
|
The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab.
The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions.
The bevacizumab is injected through the pars plana using a 30-gauge needle.
|
Experimental: Combined group
The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide.
The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions.
The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
|
The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide.
The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions.
The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of Central Retinal Thickness
Time Frame: baseline, 1, 3, 6 months after injection
|
Changes of central retinal thickness on optical coherence tomography (OCT) at baseline and 1, 3, 6 month after injection
|
baseline, 1, 3, 6 months after injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional Intravitreal Bevacizumab Injection
Time Frame: 6 months
|
Comparison of the additional intravitreal bevacizumab injection of intravitreal bevacizumab monotherapy or combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab during 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
June 5, 2012
First Submitted That Met QC Criteria
June 7, 2012
First Posted (Estimate)
June 8, 2012
Study Record Updates
Last Update Posted (Estimate)
December 4, 2012
Last Update Submitted That Met QC Criteria
December 3, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Retinal Vein Occlusion
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- PCR-11-144
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Branch Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
He Eye HospitalUnknownBranch Retinal Vein OcclusionChina
-
Kyungpook National University HospitalCompletedBranch Retinal Vein OcclusionKorea, Republic of
-
Shahid Beheshti University of Medical SciencesLabbafinejad Medical CenterUnknownBranch Retinal Vein OcclusionIran, Islamic Republic of
-
Fukushima Medical UniversityUnknown
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Medical University of ViennaRecruitingBranch Retinal Vein Occlusion | Retinal Blood Flow | Retinal Oxygen SaturationAustria
Clinical Trials on intravitreal bevacizumab monotherapy
-
University of Campania "Luigi Vanvitelli"Completed
-
Shahid Beheshti University of Medical SciencesActive, not recruitingDiabetic Macular EdemaIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesUnknownRetinal Vein Occlusion With Macular EdemaIran, Islamic Republic of
-
Sivakami A PaiUnknownStage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.United Arab Emirates
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.; Regeneron PharmaceuticalsCompletedDiabetic Macular EdemaUnited States
-
Cairo UniversityTerminatedDiabetic Retinopathy | Diabetic Macular Edema | Vascular Endothelial Growth Factor Overexpression | Macular IschemiaEgypt
-
Panhandle Eye Group, LLPCompletedDiabetic RetinopathyMexico
-
University of MalayaUnknownAge Related Macular DegenerationMalaysia
-
Instituto de Olhos de GoianiaUnknownAge Related Macular DegenerationBrazil
-
Barnes Retina InstituteMassachusetts Eye and Ear Infirmary; Long Island Vitreoretinal Consultants; Illinois... and other collaboratorsCompletedMacular Edema | Retinal Vein OcclusionUnited States